Published in Cell Cycle on January 01, 2014
Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics (2016) 0.80
Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy. Cell Cycle (2017) 0.76
Sirtuin1 Expression and Correlation with Histopathological Features in Retinoblastoma. Ocul Oncol Pathol (2015) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem (2006) 3.18
Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem (2001) 2.80
Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem (2005) 2.77
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol (2014) 1.95
SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle (2007) 1.74
The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle (2007) 1.45
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol (2003) 1.17
Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen (2011) 1.16
Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun (2008) 1.04
SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys (2014) 0.98
SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget (2014) 0.90
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
SIRT1 regulates lamellipodium extension and migration of melanoma cells. J Invest Dermatol (2014) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. Oncotarget (2014) 0.87
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res (2006) 3.17
Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle (2011) 2.12
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res (2004) 1.84
Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol (2008) 1.74
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene (2003) 1.62
Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol (2003) 1.53
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem (2008) 1.46
Molecular targets for green tea in prostate cancer prevention. J Nutr (2003) 1.43
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res (2009) 1.40
Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther (2006) 1.39
Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer (2005) 1.37
Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene (2004) 1.36
Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res (2007) 1.30
Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J (2005) 1.28
Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene (2003) 1.27
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res (2009) 1.21
Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol (2006) 1.21
Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis (2005) 1.19
Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer Ther (2004) 1.17
Melatonin in cancer management: progress and promise. Cancer Res (2006) 1.13
Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res (2005) 1.13
Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther (2007) 1.12
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 1.12
Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res (2011) 1.12
The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res (2013) 1.11
Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal (2012) 1.10
Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol (2009) 1.10
Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice. Oncogene (2003) 1.08
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials (2013) 1.07
Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol (2003) 1.05
Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle (2009) 1.04
Botanical antioxidants for chemoprevention of photocarcinogenesis. Front Biosci (2002) 1.04
Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem (2004) 1.03
The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol (2006) 1.03
Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia (2003) 1.03
Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res (2010) 1.02
Role of intrinsically disordered protein regions/domains in transcriptional regulation. Life Sci (2008) 1.01
Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem Photobiol (2005) 1.01
Circadian rhythm connections to oxidative stress: implications for human health. Antioxid Redox Signal (2013) 1.00
Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res (2010) 0.99
Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol Pharmacol (2011) 0.99
Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate (2008) 0.98
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res (2006) 0.98
Enhancement of UVB radiation-mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes. Mol Cancer Ther (2006) 0.97
Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res (2010) 0.97
Resveratrol in cancer management: where are we and where we go from here? Ann N Y Acad Sci (2011) 0.96
Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci (2013) 0.95
Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene (2004) 0.94
Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med (2010) 0.94
Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer (2010) 0.93
Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins. Cancer Lett (2006) 0.92
Ethanol impairs activation of retinoic acid receptors in cerebellar granule cells in a rodent model of fetal alcohol spectrum disorders. Alcohol Clin Exp Res (2010) 0.91
Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal (2004) 0.91
Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle (2009) 0.91
Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res (2012) 0.91
Naturally occurring organic osmolytes: from cell physiology to disease prevention. IUBMB Life (2010) 0.91
Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle (2015) 0.90
(-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle (2009) 0.88
Protein-protein interactions: principles, techniques, and their potential role in new drug development. J Biomol Struct Dyn (2011) 0.88
The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys (2011) 0.88
Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharm Res (2010) 0.87
Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. Oncotarget (2014) 0.87
Resveratrol imparts photoprotection of normal cells and enhances the efficacy of radiation therapy in cancer cells. Photochem Photobiol (2008) 0.87
Protective effect of sanguinarine on ultraviolet B-mediated damages in SKH-1 hairless mouse skin: implications for prevention of skin cancer. Photochem Photobiol (2007) 0.86
SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms. FASEB J (2009) 0.86
Polo-like kinase (Plk) 1 as a target for prostate cancer management. IUBMB Life (2005) 0.85
Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys (2010) 0.85
Ultraviolet B exposure activates Stat3 signaling via phosphorylation at tyrosine705 in skin of SKH1 hairless mouse: a target for the management of skin cancer? Biochem Biophys Res Commun (2005) 0.85
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells. J Proteome Res (2014) 0.84
Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res (2003) 0.84
Antiproliferative effects of apple peel extract against cancer cells. Nutr Cancer (2010) 0.83
The circadian control of skin and cutaneous photodamage. Photochem Photobiol (2012) 0.81
Folliculotropic mycosis fungoides with central nervous system involvement: demonstration of tumor clonality in intrafollicular T cells using laser capture microdissection. J Am Acad Dermatol (2003) 0.80
Skin, reactive oxygen species, and circadian clocks. Antioxid Redox Signal (2013) 0.80
Methaneseleninic acid and γ-Tocopherol combination inhibits prostate tumor growth in Vivo in a xenograft mouse model. Oncotarget (2014) 0.80
Ultraviolet-B radiation causes an upregulation of survivin in human keratinocytes and mouse skin. Photochem Photobiol (2004) 0.79
Antioxidants meet molecular targets for cancer prevention and therapeutics. Antioxid Redox Signal (2013) 0.76
Special issue commemorating the 65th birthday of Craig A. Elmets. Introduction. Photochem Photobiol (2015) 0.75
Sirtuins in Skin and Skin Cancers. Skin Pharmacol Physiol (2017) 0.75
Introduction to the special issue honoring Professor David R. Bickers. Photochem Photobiol (2012) 0.75